Open AccessRole of tumor-associated immune cells in prostate cancer: angel or devil?
Author(s) -
Shuiqing Wu,
Hao Su,
Yinhuai Wang,
Xiaokun Zhao
Publication year - 2019
Publication title -
asian journal of andrology/asian journal of andrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 74
eISSN - 1745-7262
pISSN - 1008-682X
DOI - 10.4103/aja.aja_47_19
Subject(s) - prostate cancer , immune system , malignancy , androgen deprivation therapy , medicine , cancer , prostate , metastasis , oncology , cancer research , tumor progression , immunotherapy , immunology
Prostate cancer is the most common malignancy in the reproductive system of older males. Androgen deprivation therapy (ADT) is an important treatment for prostate cancer patients. However, almost all prostate cancer patients unavoidably progress to the castration-resistant stage after ADT treatment. Recent studies have shown that tumor-associated immune cells play major roles in the initiation, progression, and metastasis of prostate cancer. Various phenotypes of tumor-associated immune cells have tumor-promoting or antitumor functions mediated by interacting with tumor cells. Here, we review the current knowledge of tumor-associated immune cells in prostate cancer.